Incyte Corporation - Common Stock (INCY) stock analysis
INCY · Incyte Corporation - Common Stock
Latest recorded price: USD 120.27
Model-estimated fair value: USD 103.58. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Biotechnology
At $120.27, INCY trades 16.1% above the model's base-case value of $103.58. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $81.93 in the conservative case and $129.60 in the optimistic case, with a valuation confidence score of 55/100. Fiscal 2025 figures: revenue growth 14.8%, free cash flow margin 26.3%, ROIC 63.3%. The model does not flag any risk signals for this company.
Similar companies in Healthcare
- Insmed Incorporated - Common Stock (INSM)
- Innoviva, Inc. (INVA)
- Ionis Pharmaceuticals, Inc. (IONS)
- Iovance Biotherapeutics, Inc. (IOVA)
- Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
- Korsana Biosciences, Inc. (KRSA)
- Krystal Biotech, Inc. - Common Stock (KRYS)
- Kymera Therapeutics, Inc. - Common Stock (KYMR)